✦ LIBER ✦

Co-administration of the JAK inhibitor CP-690,550 and methotrexate is well tolerated in patients with rheumatoid arthritis without need for dose adjustment

✍ Scribed by Stanley Cohen; Samuel H. Zwillich; Vincent Chow; Robert R. LaBadie; Bethanie Wilkinson

Book ID: 108642436
Publisher: John Wiley and Sons
Year: 2010
Tongue: English
Weight: 724 KB
Volume: 69
Category: Article
ISSN: 0306-5251
DOI: 10.1111/j.1365-2125.2009.03570.x

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

A phase IIb dose-ranging study of the or

A phase IIb dose-ranging study of the oral JAK inhibitor tofacitinib (CP-690,550) versus placebo in combination with background methotrexate in patients with active rheumatoid arthritis and an inadequate response to methotrexate alone

✍ Joel M. Kremer; Stanley Cohen; Bethanie E. Wilkinson; Carol A. Connell; Jonathan 📂 Article 📅 2012 🏛 John Wiley and Sons 🌐 English ⚖ 338 KB

Phase IIb dose-ranging study of the oral

Phase IIb dose-ranging study of the oral JAK inhibitor tofacitinib (CP-690,550) or adalimumab monotherapy versus placebo in patients with active rheumatoid arthritis with an inadequate response to disease-modifying antirheumatic drugs

✍ Roy Fleischmann; Maurizio Cutolo; Mark C. Genovese; Eun Bong Lee; Keith S. Kanik 📂 Article 📅 2012 🏛 John Wiley and Sons 🌐 English ⚖ 424 KB 👁 4 views